Pfizer Inc. Files 8-K on Financials and Operations

Ticker: PFE · Form: 8-K · Filed: 2025-04-29T00:00:00.000Z

Sentiment: neutral

Topics: financial-results, operations, disposal-costs

Related Tickers: PFE

TL;DR

Pfizer dropped an 8-K on April 29th covering financials, operations, and exit costs.

AI Summary

On April 29, 2025, Pfizer Inc. filed an 8-K report detailing results of operations and financial condition. The filing also covers cost associated with exit or disposal activities and includes financial statements and exhibits. The report confirms Pfizer Inc. is a Delaware-incorporated company with its principal executive offices located at 66 Hudson Boulevard East, New York, NY.

Why It Matters

This filing provides crucial updates on Pfizer's financial performance and operational activities, which can influence investor decisions and market perception.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What specific financial results are being reported by Pfizer Inc. in this 8-K?

The filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.

What kind of 'exit or disposal activities' is Pfizer Inc. reporting costs for?

The filing mentions 'Cost Associated with Exit or Disposal Activities' but does not specify the nature of these activities in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported is April 29, 2025, which is also the date of the report.

What is Pfizer Inc.'s fiscal year end?

Pfizer Inc.'s fiscal year ends on December 31.

What is the Commission File Number for Pfizer Inc.'s 8-K filing?

The Commission File Number for this filing is 1-3619.

From the Filing

0000078003-25-000111.txt : 20250429 0000078003-25-000111.hdr.sgml : 20250429 20250429080249 ACCESSION NUMBER: 0000078003-25-000111 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250429 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250429 DATE AS OF CHANGE: 20250429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 25882766 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20250429.htm 8-K pfe-20250429 0000078003 false 0000078003 2025-04-29 2025-04-29 0000078003 us-gaap:CommonStockMember 2025-04-29 2025-04-29 0000078003 pfe:NotesDue20271.000Member 2025-04-29 2025-04-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2025 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 2.02 Results of Operations and Financial Condition On April 29, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the first quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes o

View on Read The Filing